IGF2 and colorectal carcinoma: In summary, IGF2 methylation in PBLs is significantly associated with the risk and prognosis of CRC, suggesting an important role for IGF2 methylation as a blood-based predictive biomarker to identify of individuals at high risk of developing CRC; meanwhile, PBL IGF2 methylation might also serve as a predictive biomarker for CRC prognosis.